Ref (type) | Population | Outcome, Interventions | Results and statistical analysis | Effect size | Favours |
Health-related quality of life | |||||
[65]
Systematic review |
712 people with COPD 2 RCTs in this analysis |
Mean change from baseline in Chronic Respiratory Disease Questionnaire
6 months
10 with fluticasone plus salmeterol 5 with placebo |
WMD 5.0 95% CI 2.48 to 7.52 P = 0.0001 |
Effect size not calculated | fluticasone plus salmeterol |
[65]
Systematic review |
3346 people with COPD 4 RCTs in this analysis |
Mean change in St George's Respiratory Questionnaire (SGRQ)
6 months to 3 years
with fluticasone plus salmeterol with placebo Absolute numbers not reported |
–2.9 units 95% CI –3.61 units to –2.18 units P <0.00001 |
Effect size not calculated | fluticasone plus salmeterol |
[65]
Systematic review |
923 people with COPD 2 RCTs in this analysis |
Mean change in SGRQ
12 months
with budesonide plus formoterol with placebo Absolute numbers not reported |
–6.06 units v placebo 95% CI –7.90 units to –4.22 units P <0.00001 |
Effect size not calculated | budesonide plus formoterol |
[68]
RCT 3-armed trial |
224 people with COPD |
Change in SGRQ
4 weeks
–2.4 with fluticasone 500 micrograms plus salmeterol 50 micrograms twice daily +1.5 with placebo |
P <0.05 |
Effect size not calculated | fluticasone plus salmeterol |